This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Yan Leyfman, MD
yleyfman.bsky.social
did:plc:c5m2uulwwds45iwdkxzm5wtu
It allowed transition to BCMA CAR-T (cilta-cel or ide-cel) in heavily pretreated, high-risk patients, including many who would not have qualified for clinical trials.
2025-08-02T23:00:45.425Z